Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic - 22/02/24
, Chris Gast, PhD d, Sonia Mazara, MD a, Katy Rodriguez, MD a, Nadia Rosario, MD b, Yiting Zhang, MSc e, Bernardo A Mainou, PhD e, Jose Jimeno, MD f, Gabriela Aguirre, MSc g, Ricardo Rüttimann, MD gSummary |
Background |
The novel oral poliovirus vaccine type 2 (nOPV2) is now authorised by a WHO emergency use listing and widely distributed to interrupt outbreaks of circulating vaccine-derived poliovirus type 2. As protection of vulnerable populations, particularly young infants, could be facilitated by shorter intervals between the two recommended doses, we aimed to assess safety and non-inferiority of immunogenicity of nOPV2 in 1-week, 2-week, and 4-week schedules.
Methods |
In this phase 3, open-label, randomised trial, healthy, full-term, infants aged 6–8 weeks from a hospital or a clinic in the Dominican Republic were randomly allocated (1:1:1 ratio) using a pre-prepared, computer-generated randomisation schedule to three groups to receive two doses of nOPV2 immunisations with a 1-week interval (group A), 2-week interval (group B), or 4-week interval (group C). The nOPV2 vaccine was given at a 0·1 mL dose and contained at least 105 50% cell culture infective dose. Neutralising antibodies against poliovirus types 1, 2, and 3 were measured before each immunisation and 4 weeks after the second dose. The primary outcome was the type 2 seroconversion rate 28 days after the second dose, and the non-inferiority margin was defined as a lower bound 95% CI of greater than –10%. Safety and reactogenicity were assessed through diary cards completed by the parent or guardian. The trial is registered with ClinicalTrials.gov, NCT05033561.
Findings |
We enrolled 905 infants between Dec 16, 2021, and March 28, 2022. 872 infants were included in the per-protocol analyses: 289 in group A, 293 in group B, and 290 in group C. Type 2 seroconversion rates were 87·5% (95% CI 83·2 to 91·1) in group A (253 of 289 participants), 91·8% (88·1 to 94·7) in group B (269 of 293 participants), and 95·5% (92·5 to 97·6) in group C (277 of 290 participants). Non-inferiority was shown for group B compared with group C (difference in rates –3·7; 95% CI –7·9 to 0·3), but not for group A compared with group C (–8·0; –12·7 to –3·6). 4 weeks after the second nOPV2 dose, type 2 neutralising antibodies increased in all three groups such that over 95% of each group was seroprotected against polio type 2, although final geometric mean titres tended to be highest with longer intervals between doses. Immunisation with nOPV2 was well tolerated with no causal association to vaccination of any severe or serious adverse event; one death from septic shock during the study was unrelated to the vaccine.
Interpretation |
Two nOPV2 doses administered 1 week or 2 weeks apart from age 6 weeks to 8 weeks were safe and immunogenic. Immune responses after a 2-week interval were non-inferior to those after the standard 4-week interval, but marked responses after a 1-week interval suggest that schedules with an over 1-week interval can be used to provide flexibility to campaigns to improve coverage and hasten protection during circulating vaccine-derived poliovirus type 2 outbreaks.
Funding |
Bill & Melinda Gates Foundation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 24 - N° 3
P. 275-284 - mars 2024 Retour au numéro
Article précédent
- Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study
- Antoine Nkuba-Ndaye, Angele Dilu-Keti, Tamara Tovar-Sanchez, Mamadou Saliou Kalifa Diallo, Daniel Mukadi-Bamuleka, Richard Kitenge, Pierre Formenty, Anaïs Legand, François Edidi-Atani, Guillaume Thaurignac, Raphael Pelloquin, Placide Mbala-Kingebeni, Abdoulaye Toure, Ahidjo Ayouba, Jean-Jacques Muyembe-Tamfum, Eric Delaporte, Martine Peeters, Steve Ahuka-Mundeke, Les Vainqueurs d’Ebola Study Group, Steve Ahuka-Mundeke, Nella Bisento-Ngafa, Junior Bulabula-Penge, Bernice Danga-Yema, François Eddi-Atani, Eddy Kinganda-Lusamaki, Antoine Nkuba-Ndaye, Fabrice Mambu Mbika, Gabriel Kabamba Lungenyi, Meris Matondo Kiamfumu, Placide Mbala-Kingebeni, Daniel Mukadi-Bamuleka, Jean-Jacques Muyembe-Tamfum, Eric Delaporte, Ahidjo Ayouba, Julie Boullin, Angèle Dilu-Keti, Audrey Lacroix, Martine Peeters, Raphael Pelloquin, Guillaume Thaurignac, Tamara Tovar Sanchez, Richard Kitenge, Pierre Formenty, Anaïs Legand, Eric Panzi-Kalunda, Callixte Kakule-Sadiki, Guillaume Kambale-Kasyamboko, Nelson Kambale-Sivihwa, Sheila Kavira-Muhesi, Eli Kavoyo-Mbayayi, Divine Kitsa-Mutsumbirwa, Fyfy Mbelu-Matulu, Noella Mulopo-Mukanya, Elias Mumbere-Kalemekwa, Grace Paluku-Salambongo, Abdoulaye Touré, Mamadou Saliou Kalifa Diallo
- Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial
- Anne Wajja, Beatrice Nassanga, Agnes Natukunda, Joel Serubanja, Josephine Tumusiime, Helen Akurut, Gloria Oduru, Jacent Nassuuna, Joyce Kabagenyi, Hazel Morrison, Hannah Scott, Rebecca Powell Doherty, Julia L Marshall, Ingrid Cabrera Puig, Stephen Cose, Pontiano Kaleebu, Emily L Webb, Iman Satti, Helen McShane, Alison M Elliott, TB042 Study Team, Milly Namutebi, Esther Nakazibwe, Caroline Onen, Barbara Apuule, Florence Akello, Mike Mukasa, Marble Nnaluwooza, Moses Sewankambo, Sam Kiwanuka, Fred Kiwudhu, Esther Imede, Gyaviira Nkurunungi, Prossy Kabuubi Nakawungu, Grace Kabami, Emmanuel Nuwagaba, Mirriam Akello
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?